CG인바이츠

083790KOSDAQ자연과학 및 공학 연구개발업

53.2 / 100

Reference Date: 2026-04-13

Financial Score20.0 / 40

News Sentiment14.2 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly down 4.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CGinBites operates in pharmaceutical R&D, AI healthcare solutions, and thermal patch manufacturing, with key projects including the approved drug 'Acell克斯' and ongoing clinical trials for cancer treatments. The company leads medical innovation through precision medicine platforms based on genomic analysis and AI-driven digital healthcare solutions. It also contributes to ecosystem expansion via venture investments and startup support.

Number of Employees

92people

Average Salary

60.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

0.84Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE

-10.45Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

13.45Industry Average 7.520.5Point

1.8x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲163.2% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.3% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 0Negative 0Average Sentiment Score 70

Positive
신용규 인바이츠 회장 "IT통 이사회 진입…역량 검증 완료" [현장+]
신용규 인바이츠 회장이 남민우 회장의 이사회 진입을 통해 인바이츠의 디지털헬스케어 역량을 강화할 것이라고 밝혔습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 1,304Won52-week high 2,29052-week low 1,220

1-month return2.0Point

1m -4.33% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19